Heron Therapeutics (HRTX) Non Operating Interest Expenses (2012 - 2017)

Heron Therapeutics (HRTX) has reported Non Operating Interest Expenses for 6 consecutive years, with $1.0 million the latest figure, recorded in Q1 2017.

• For the quarter ending Q1 2017, Non Operating Interest Expenses rose 674.44% year-over-year to $1.0 million; the trailing twelve-month figure through Mar 2017 stood at $3.4 million (up 300.81% YoY), and the FY2025 full-year result was $9.6 million, up 59.23% from the prior year.
• Non Operating Interest Expenses fell to $1.0 million in Q1 2017 per HRTX's latest filing, from $1.3 million in the prior quarter.
• Across five years, Non Operating Interest Expenses topped out at $1.3 million in Q4 2016 and bottomed at $133000.0 in Q1 2016.
• Historically, Non Operating Interest Expenses has averaged $367529.4 across 5 years, with a median of $227000.0 in 2014.
• The sharpest annual moves came in 2016 and 2017: Non Operating Interest Expenses slumped 42.67% in 2016, then jumped 674.44% in 2017.
• Over 5 years, Non Operating Interest Expenses stood at $212000.0 in 2013, then rose by 7.08% to $227000.0 in 2014, then grew by 8.81% to $247000.0 in 2015, then soared by 414.17% to $1.3 million in 2016, then fell by 18.9% to $1.0 million in 2017.
• According to Business Quant data, Non Operating Interest Expenses over the past three periods registered $1.0 million, $1.3 million, and $886000.0 for Q1 2017, Q4 2016, and Q3 2016 respectively.